Literature DB >> 12181644

Identification of polymorphisms in the human SHP1 gene.

Henian Cao1, Robert A Hegele.   

Abstract

Because mutations in human SHP1 underlie obesity and diabetes, SHP1 is a candidate gene for human lipodystrophy syndromes. To identify possible disease mutations and/or common single-nucleotide polymorphisms (SNPs), we developed primer pairs to amplify the promoter and coding region of SHP1. We used these pairs to sequence SHP1 in lipodystrophy patients who had no mutations in known lipodystrophy genes, and also in normal control subjects. We found no rare SHP1 coding sequence variants that were exclusive to patients with lipodystrophy. However, we found four polymorphisms, namely, an SNP [-394]C>T in the promoter, a micro-deletion polymorphism [-195]delCTGA in the promoter, a missense SNP 541G>C in exon 1 (which changed the amino acid sequence G171A), and an SNP 903C>T in exon 2. The findings suggest that SHP1 mutations are not commonly seen in patients with lipodystrophy who had no mutations in known disease genes. However, the identification of amplification primers and polymorphisms provides tools to further investigate SHP1 for association with other phenotypes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12181644     DOI: 10.1007/s100380200062

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  13 in total

Review 1.  Role of nuclear receptor SHP in metabolism and cancer.

Authors:  Yuxia Zhang; Curt H Hagedorn; Li Wang
Journal:  Biochim Biophys Acta       Date:  2010-10-20

2.  ASK1/2 signaling promotes inflammation in a mouse model of neutrophilic dermatosis.

Authors:  Sarang Tartey; Prajwal Gurung; Tejasvi Krishna Dasari; Amanda Burton; Thirumala-Devi Kanneganti
Journal:  J Clin Invest       Date:  2018-04-09       Impact factor: 14.808

3.  Insights into the binding mode and mechanism of action of some atypical retinoids as ligands of the small heterodimer partner (SHP).

Authors:  Marco Cellanetti; Viswanath Gunda; Li Wang; Antonio Macchiarulo; Roberto Pellicciari
Journal:  J Comput Aided Mol Des       Date:  2010-09-30       Impact factor: 3.686

4.  Tyrosine Kinase SYK Licenses MyD88 Adaptor Protein to Instigate IL-1α-Mediated Inflammatory Disease.

Authors:  Prajwal Gurung; Gaofeng Fan; John R Lukens; Peter Vogel; Nicholas K Tonks; Thirumala-Devi Kanneganti
Journal:  Immunity       Date:  2017-04-11       Impact factor: 31.745

5.  Novel polymorphisms of nuclear receptor SHP associated with functional and structural changes.

Authors:  Taofeng Zhou; Yuxia Zhang; Antonio Macchiarulo; Zhihong Yang; Marco Cellanetti; Eliecer Coto; Pingyi Xu; Roberto Pellicciari; Li Wang
Journal:  J Biol Chem       Date:  2010-06-01       Impact factor: 5.157

Review 6.  Autoinflammatory Skin Disorders: The Inflammasomme in Focus.

Authors:  Prajwal Gurung; Thirumala-Devi Kanneganti
Journal:  Trends Mol Med       Date:  2016-06-03       Impact factor: 11.951

7.  Cutting Edge: Dysregulated CARD9 Signaling in Neutrophils Drives Inflammation in a Mouse Model of Neutrophilic Dermatoses.

Authors:  Sarang Tartey; Prajwal Gurung; Parimal Samir; Amanda Burton; Thirumala-Devi Kanneganti
Journal:  J Immunol       Date:  2018-08-06       Impact factor: 5.422

Review 8.  Function and regulation of IL-1α in inflammatory diseases and cancer.

Authors:  Ankit Malik; Thirumala-Devi Kanneganti
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988

9.  A pleiotropic role for the orphan nuclear receptor small heterodimer partner in lipid homeostasis and metabolic pathways.

Authors:  Gabriella Garruti; Helen H Wang; Leonilde Bonfrate; Ornella de Bari; David Q-H Wang; Piero Portincasa
Journal:  J Lipids       Date:  2012-04-22

10.  RIP1-driven autoinflammation targets IL-1α independently of inflammasomes and RIP3.

Authors:  John R Lukens; Peter Vogel; Gordon R Johnson; Michelle A Kelliher; Yoichiro Iwakura; Mohamed Lamkanfi; Thirumala-Devi Kanneganti
Journal:  Nature       Date:  2013-05-26       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.